Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
JHSPH Center for Clinical Trials
With
GlaxoSmithKline
This trial will attempt to investigate whether asthmatic patients that are well controlled with low-dose twice daily inhaled corticosteroid (ICS) therapy can safely be switched to other modes of controller therapy without loss of asthma control. Patients demonstrating good control on twice-daily low-dose ICS will be randomized to one of three treatment groups: once-daily low-dose ICS (fluticasone), leukotriene receptor antagonist (montelukast), or once-daily combination therapy (fluticasone-salmeterol).
Age
6–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
physician-diagnosed asthma
age 6 or older
pre-bronchodilator forced expiratory volume (FEV1) of at least 60% of predicted
beta-agonist reversibility OR airways hyperreactivity by methacholine challenge
Juniper Asthma Control Score of 1.5 or greater if not on daily controller
good current health
You may not be if
current or past smoking (greater than 20 pack-years)
chronic or current oral steroid therapy
pregnancy, lack of effective contraception (when appropriate), lactation